The effect of synthetic ceramide analogues on gastritis and esophagitis in rats

Abstract

The effects of ceremide analogues on esophagitis and gastritis in rats were examined. Gastritis induced by indomethacin was significantly reduced after CY3325 and CY3723 treatment, whereas other analogues had no effect. The amount of malondialdehyde in gastritis was significantly reduced by CY3325 or CY 3723. CY3325 or CY 3723 decreased the glutathione levels in gastritis. The myeloperoxidase level in gastritis is increased, and its increment was decreased by CY3325 and CY3723. In reflux esophagitis, the ulceration was decreased by CY3325, CY3723. The gastric volume and acid output are reduced, whereas the pH value is increased by CY3325 or CY3723 after esophagitis. These results suggest that ceramide analogues, CY3325 and CY3723, can prevent the development of gastritis and reflux esophagitis in rats.

Non-targeted metabolomics reveals diagnostic biomarker in the tongue coating of patients with chronic gastritis

“…XO catalyzes the reaction of hypoxanthine to xanthine and xanthine to uric acid [41]. Each reaction can produce a large amount of superoxide anion and hydrogen peroxide which results in oxidative stress and oxidative stress damage [42][43][44]. According to our study, the level of xanthine, inosine and adenosine were significantly increased in the tongue coating of CG patients, which indicated the disordered of purine metabolic pathway and a large number of oxygen free radicals may be produced leading to the occurrence of CG.…”